Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

Phase 2TerminatedNCT03540485

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla25 enrolled

Overview

Phase I / II randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin administration combined with ocrelizumab in patients with Progressive Multiple Primary Sclerosis.

Multiple sclerosis (MS), the most common inflammatory disease of the central nervous system in young adults, has a huge social and health interest, especially the primary progressive (PP-) course, in which the disability is very fast accumulated and currently there are no available treatments in Spain. PP-MS is characterized by neuro-inflammation and, especially, by neurodegeneration, with brain atrophy as key feature. It has been proposed that PP-MS therapies should combine anti-inflammatory and neuroprotective activities. The investigators have shown that melatonin, an immunomodulatory, antioxidant and neuroprotective compound, ameliorates the disease and modulates the pathogenic/protective immune responses in a MS animal model. Moreover, melatonin caused a long-term improvement of disability on a PP-MS patient. Thus, melatonin could be of interest in the therapy of PP-MS. So far, ocrelizumab, recently authorized by the European Medicines Agency and incorporated into the portfolio of the Spanish National Health System in December 2018, is the only therapy that has shown some therapeutic efficacy on the decrease in long-term disability. The purpose of this study is to determine the feasibility of using melatonin combined with ocrelizumab to treat PP-MS. Thus, the investigators propose a randomized, single-blind, placebo-controlled study on the safety and efficacy of melatonin combined with ocrelizumab on PP-MS patients. The investigators will assess the daily administration to patients treated with ocrelizumab for at least 9 months of one oral dose of melatonin containing 100mg during 24 months on patients safety and its effects over brain atrophy progression, Expanded Disability Status Scale scores, quality of life, MS symptoms, circadian impairment and levels of markers of central nervous system inflammation, axonal damage, Blood-brain barrier disruption and oxidative stress.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

Conditions

Sclerosis, Multiple Autoimmune Diseases of the Nervous System Nervous System Diseases Autoimmune Diseases

Interventions

MelatoninDRUG

Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm

PlaceboOTHER

Daily administration of placebo orally, for 24 months between 10pm to 11pm

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients who come to the Multiple Sclerosis Unit of the Department of Neurology of the Virgen Macarena University Hospital (Seville) or Vithas Nisa Seville Hospital or Virgen del Rocío University Hospital (Seville), and who meet the following criteria: * Have progressive primary multiple sclerosis according to McDonald's diagnostic criteria modified in 2010. * Age between 18 and 65 years old. * Neurological impairment measured with the Expanded Disability Status Scale (EDSS) scale between 2 and 7 (both included, without disability or only clinical symptoms up to ambulatory capacity with bilateral support). * Not having received any immunomodulatory, except for ocrelizumab in stable doses for at least 9 months before inclusion in this study, or immunosuppressive treatment (including cytostatic agents) during the 3 months prior to participation in the trial. * If there is a possibility of pregnancy (in women of childbearing age (15 to 44 years)) or paternity, accept the use of a highly effective method of birth control recommended by the Clinical Trial Facilitation Group (CTFG) during the treatment phase of the trial.. * Not having consumed melatonin or other dietary supplements (antioxidants or vitamins (tripling the recommended daily doses) during the month prior to participation in the trial. * Ability to give informed consent and comply with the visits scheduled in the study. Exclusion Criteria: * Alternative diagnosis that explains both the neurological disability and the findings in nuclear magnetic resonance. * Clinically significant medical problems that, in the opinion of the investigators, may cause tissue damage in the central nervous system or limit its repair, or that may expose the patient to unjustified risks or damages, or cause the patient not to complete the study. * Clinical history of hypersensitivity reactions to melatonin. * Pregnancy or lactation, or planning to become pregnant or patients of childbearing age not subject to birth control methods (recommended by the Clinical Trial Facilitation Group (CTFG)). * Abnormal results in basal blood tests, defined as: * Serum levels of alanine transaminase or aspartate transaminase greater than 1.5 times the upper limit of normal values. * Total leukocyte count less than 3,000 / mm3. * Platelet count less than 85,000 / mm3. * Serum creatinine level greater than 2.0 mg / dL or glomerular filtration rate less than 30. * Neurological deterioration measured with the Expanded Disability Status Scale scale of less than 2 or greater than 7. * Be receiving any immunosuppressive therapy, except for ocrelizumab, including cytostatic agents.

Locations (3)

Virgen Macarena Hospital

Seville, Seville, Spain

Virgen del Rocio University Hospital

Seville, Seville, Spain

Hospital Vithas Nisa Sevilla

Seville, Seville, Spain

Outcomes

Primary Outcomes

Rates of neurological impairment

Individualized rates of disease progression will be quantified using the rates of neurological impairment (Kurtzke Expanded Disability Status Scale). The scale provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.

Time frame: 2 years

Rates of disability

Individualized rates of disease progression will be also quantified using the rates of disability (Multiple Sclerosis Functional Composite - MSFC scale).The MSFC measures are administered in person by a trained examiner. The MSFC can produce scores for each of the three individual measures (measure leg function/ambulation, arm/hand function, and cognitive function) as well as a composite score. Total administration time for all three measures should be approximately 20-30 minutes. Scores on component measures are converted to standard scores (z-scores), which are averaged to form a single MSFC score.

Time frame: 2 years

Secondary Outcomes

Number of participants with treatment-related adverse events

To determine the incidence of adverse events and any abnormal laboratory values

Time frame: monthly from date of randomization until the end of the follow-up, assessed up to 24 months

Cerebral atrophy

Cerebral atrophy will be measured through magnetic resonance imaging

Time frame: In every study visit, assessed up to 24 months

Fatigue

Fatigue will be assessed using the Modified Fatigue Impact Scale scale (MFIS), a modified form of the Fatigue Impact Scale (Fisk et al, 1994b) based on items derived from interviews with multiple sclerosis patients concerning how fatigue impacts their lives. The total score for the MFIS is the sum of the scores for the 21 items. Items on the MFIS can be aggregated into three subscales (physical, cognitive, and psychosocial), as well as into a total MFIS score. All items are scaled so that higher scores indicate a greater impact of fatigue on a person's activities.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.